# The Efficacy and Safety of Combining Probiotic VSL#3 With Vedolizumab for the Treatment of Moderate Ulcerative Colitis

> **NCT06609447** · PHASE4 · RECRUITING · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 100 (estimated)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DIETARY_SUPPLEMENT:** VSL#3
- **DIETARY_SUPPLEMENT:** Placebo
- **DRUG:** Vedolizumab

## Key facts

- **NCT ID:** NCT06609447
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-21
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06609447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06609447, "The Efficacy and Safety of Combining Probiotic VSL#3 With Vedolizumab for the Treatment of Moderate Ulcerative Colitis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06609447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*